Senti Biosciences Inc

Senti Biosciences, Inc. operates as a biotechnology company. It develops gene circuit technology platforms which enable the development of next-generation cell and gene therapies. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML –

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS -

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on October 27, 2022, the compensation committee of Senti Bio's board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company's common stock with a per share exercise price of $2.39. These awards were made under the Company's 2022 Inducement Equity Plan (the Plan).

Senti Bio Announces New Employment Inducement Grants

Innovid Corp

Workhorse Group

While the below market ideas may very well represent the best penny stocks under $3 to buy now, you must realize the dirty little secret. Usually, when publicly traded securities fall this low, it's not for good reasons.

7 Best Penny Stocks Under $3 to Buy Now

Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

American Virtual Cloud Technologies

BigBear.ai Holdings

Here's what you need to know about buying penny stocks on September 29th The post Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today

Mind Medicine MindMed

PolyPid

Biotech penny stocks to watch as stock market crash continues today. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.

Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET.

Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Chardan NexTech Acquisition 2 Corp

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used to support the unique needs of its clients.

Chardan Announces Launch of ChEF (Chardan Equity Facility)

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 -

Senti Bio Reports Second Quarter Financial Results and Business Updates

The stock price of Senti Biosciences (SNTI) surged by 68.28% in the previous trading session. These are some details you should know.

Senti Biosciences (SNTI) Surged 68.28%: Details You Should Know

On most days, Senti Biosciences (NASDAQ: SNTI ) flies under the radar on Wall Street. Today, however, is different as SNTI stock is flying high.

SNTI Stock Alert: What to Know About Red-Hot Senti Biosciences Today

News for Senti Biosciences Inc Stock (SNTI)